COMPASS THERAPEUTICS, INC. (CMPX) Free cash flow
- Free cash flow · 12 months (USD): Value $-56.38M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-56.38M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-56.11M − $265.00K ≈ $-56.38M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-56.11M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.76× | Operating cash flow / net income. Period ending 2026-06-30. $-56.11M ÷ $-73.45M ≈ 0.76× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -56.11M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 265.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -56.38M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -73.45M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-56.38M | (m) | $-56.11M | $265.00K | (m) | (m) | (m) | $-73.45M | (m) | (m) | (m) | 0.76× |
| 2026-03-31 | $-53.29M | (m) | $-53.20M | $89.00K | (m) | (m) | (m) | $-68.17M | (m) | (m) | (m) | 0.78× |
| 2025-12-31 | $-49.17M | (m) | $-49.14M | $25.00K | (m) | (m) | (m) | $-66.49M | (m) | (m) | (m) | 0.74× |
| 2025-09-30 | $-45.08M | (m) | $-45.05M | $25.00K | (m) | (m) | (m) | $-65.81M | (m) | (m) | (m) | 0.68× |
| 2025-06-30 | $-45.31M | (m) | $-45.25M | $62.00K | (m) | (m) | (m) | $-62.03M | (m) | (m) | (m) | 0.73× |
| 2025-03-31 | $-44.24M | (m) | $-44.17M | $62.00K | (m) | (m) | (m) | $-55.22M | (m) | (m) | (m) | 0.80× |
| 2024-12-31 | $-44.90M | (m) | $-44.85M | $44.00K | (m) | (m) | (m) | $-49.38M | (m) | (m) | (m) | 0.91× |
| 2024-09-30 | $-48.10M | (m) | $-48.05M | $53.00K | (m) | (m) | (m) | $-47.76M | (m) | (m) | (m) | 1.01× |
| 2024-06-30 | $-42.94M | (m) | $-42.92M | $19.00K | (m) | (m) | (m) | $-47.24M | (m) | (m) | (m) | 0.91× |
| 2024-03-31 | (m) | (m) | $-42.28M | (m) | (m) | (m) | (m) | $-45.44M | (m) | (m) | (m) | 0.93× |
| 2023-12-31 | $-40.65M | (m) | $-40.62M | $30.00K | (m) | (m) | (m) | $-42.49M | (m) | (m) | (m) | 0.96× |
| 2023-09-30 | $-38.98M | (m) | $-38.91M | $75.00K | (m) | (m) | (m) | $-40.67M | (m) | (m) | (m) | 0.96× |
| 2023-06-30 | $-44.02M | (m) | $-43.92M | $92.00K | (m) | (m) | (m) | $-42.68M | (m) | (m) | (m) | 1.03× |
| 2023-03-31 | $-38.43M | (m) | $-38.41M | $18.00K | (m) | (m) | (m) | $-39.90M | (m) | (m) | (m) | 0.96× |
| 2022-12-31 | $-34.34M | (m) | $-34.13M | $212.00K | (m) | (m) | (m) | $-39.23M | (m) | (m) | (m) | 0.87× |
| 2022-09-30 | $-29.08M | (m) | $-28.15M | $935.00K | (m) | (m) | (m) | $-40.61M | (m) | (m) | (m) | 0.69× |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-23.64M | (m) | $-22.00M | $1.63M | (m) | (m) | (m) | $-81.92M | (m) | (m) | (m) | 0.27× |
| 2021-12-31 | $-21.23M | (m) | $-19.67M | $1.57M | (m) | (m) | (m) | $-82.18M | (m) | (m) | (m) | 0.24× |
| 2021-09-30 | $-22.45M | (m) | $-21.57M | $874.00K | (m) | (m) | (m) | $-77.59M | (m) | (m) | (m) | 0.28× |
| 2021-06-30 | $-25.80M | (m) | $-25.29M | $514.00K | (m) | (m) | (m) | $-80.76M | (m) | (m) | (m) | 0.31× |
| 2021-06-20 | $-25.80M | (m) | $-25.29M | $514.00K | (m) | (m) | (m) | $-80.76M | (m) | (m) | (m) | 0.31× |
| 2021-03-31 | $-24.87M | (m) | $-24.65M | $222.00K | (m) | (m) | (m) | $-30.52M | (m) | (m) | (m) | 0.81× |
| 2020-12-31 | $-26.91M | (m) | $-26.80M | $106.00K | (m) | (m) | (m) | $-29.50M | (m) | (m) | (m) | 0.91× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-21.12M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-11.98M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $-32.11K | (m) | (m) | (m) | (m) | $-37.48K | (m) | (m) | (m) | 0.86× |
| 2019-12-31 | (m) | (m) | $-34.52K | (m) | (m) | (m) | (m) | $-40.41K | (m) | (m) | (m) | 0.85× |
| 2019-09-30 | (m) | (m) | $-37.55K | (m) | (m) | (m) | (m) | $-38.87K | (m) | (m) | (m) | 0.97× |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-19.60M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $-32.76K | (m) | (m) | (m) | (m) | $-36.04K | (m) | (m) | (m) | 0.91× |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |